Commitments, Contingencies, and Concentration Risk (Details)
|
|
|
|
|
|
|
|
|
|
3 Months Ended |
6 Months Ended |
12 Months Ended |
|
|
|
|
|
|
|
|
Apr. 21, 2026
USD ($)
|
Feb. 16, 2026 |
Nov. 30, 2025
USD ($)
|
Sep. 05, 2025
USD ($)
|
Dec. 13, 2024
USD ($)
|
Nov. 01, 2023 |
May 15, 2023
USD ($)
|
May 15, 2023
USD ($)
robot
|
May 12, 2023
USD ($)
robot
|
Jan. 01, 2022
USD ($)
|
Jun. 30, 2026
USD ($)
shares
|
Jun. 30, 2025 |
Jun. 30, 2026
USD ($)
robot
shares
|
Jun. 30, 2025 |
Dec. 31, 2025
USD ($)
robot
|
Jun. 16, 2025
USD ($)
|
Dec. 31, 2024
USD ($)
|
Jun. 30, 2024
shares
|
Jun. 24, 2024
shares
|
Nov. 30, 2023
USD ($)
|
Nov. 13, 2023
USD ($)
|
Jan. 09, 2023
USD ($)
|
| Commitments, Contingencies, and Concentration Risk (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Company owes services |
$ 845,891
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Settlement agreement description |
|
On
February 16, 2026, the Company entered into a settlement agreement to fully settle the Encompass Purchase liability for an aggregate
amount of $650,000. The settlement consists of (i) a cash payment of $50,000, (ii) issuance of Company shares with an aggregate fair
value of $400,000, and (iii) assignment of a loan liability of $200,000. The Company paid $50,000 per the settlement agreement and recognized
a loan liability of $200,000 during the six months ended June 30, 2026. The issuance of Company shares with an aggregate fair value of
$400,000 remains pending as of June 30, 2026.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Encompass purchase liability |
|
|
|
|
|
|
|
|
|
|
$ 400,000
|
|
$ 400,000
|
|
$ 650,000
|
|
$ 263,918
|
|
|
|
|
|
| Plan provides initial shares equal (in Shares) | shares |
|
|
|
|
|
|
|
|
|
|
|
|
31,918
|
|
|
|
|
|
|
|
|
|
| Interest rate |
|
|
|
|
|
|
|
|
|
|
15.00%
|
|
15.00%
|
|
|
|
|
|
|
|
|
|
| Excise tax payable |
|
|
|
|
|
|
|
|
|
|
$ 0
|
|
$ 0
|
|
$ 1,200,000
|
|
$ 1,000,000
|
|
|
|
|
|
| Interest rate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
13.50%
|
|
5.50%
|
|
|
|
|
|
| Periodic payment |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 250,000
|
|
|
|
|
|
|
|
| Purchase commitment amount, payments made |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 386,663
|
|
$ 82,677
|
|
|
|
|
|
| Purchase Agreement for Telepresence Robots [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Commitments, Contingencies, and Concentration Risk (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of robots purchased (in robot) | robot |
|
|
|
|
|
|
|
|
|
|
|
|
20
|
|
20
|
|
|
|
|
|
|
|
| Total purchase commitment |
|
|
|
|
|
|
|
|
|
|
|
|
$ 711,900
|
|
$ 711,900
|
|
|
|
|
|
|
|
| Unpaid commitment amount |
|
|
|
|
|
|
|
|
|
|
$ 179,900
|
|
$ 179,900
|
|
$ 179,900
|
|
179,900
|
|
|
|
|
|
| Percentage of monthly revenue generated from telepresence robots, considered for payment |
|
|
|
|
|
|
|
|
80.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Telepresence robots deployed (in robot) | robot |
|
|
|
|
|
|
|
|
|
|
|
|
8
|
|
8
|
|
|
|
|
|
|
|
| Total number of deployed telepresence robots (in robot) | robot |
|
|
|
|
|
|
|
|
11
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of robots for which lifetime use payments is to be made (in robot) | robot |
|
|
|
|
|
|
|
|
|
|
|
|
125
|
|
125
|
|
|
|
|
|
|
|
| Amount paid by investor |
|
|
|
|
|
|
|
|
$ 352,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Customer Concentration Risk [Member] | Three Customers [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Commitments, Contingencies, and Concentration Risk (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Concentration risk percentage |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
45.00%
|
|
|
|
|
|
|
|
| Customer Concentration Risk [Member] | Three Customers [Member] | Accounts Receivable [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Commitments, Contingencies, and Concentration Risk (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Concentration risk percentage |
|
|
|
|
|
|
|
|
|
|
|
|
23.00%
|
|
43.00%
|
|
|
|
|
|
|
|
| Customer Concentration Risk [Member] | One Customer [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Commitments, Contingencies, and Concentration Risk (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Concentration risk percentage |
|
|
|
|
|
|
|
|
|
|
46.00%
|
29.00%
|
43.00%
|
28.00%
|
|
|
|
|
|
|
|
|
| Supplier Concentration Risk [Member] | Accounts Payable and Accrued Liability [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Commitments, Contingencies, and Concentration Risk (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Concentration risk percentage |
|
|
|
|
|
|
|
|
|
|
|
|
78.00%
|
|
31.00%
|
|
|
|
|
|
|
|
| Subsequent Event [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Commitments, Contingencies, and Concentration Risk (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Settlement agreement description |
|
Subsequent
to the balance sheet date, on February 16, 2026, the Company entered into a settlement agreement to fully settle the Encompass Purchase
liability for an aggregate amount of $650,000. The settlement consists of (i) a cash payment of $50,000, (ii) issuance of Company shares
with an aggregate fair value of $400,000, and (iii) assignment of a loan liability of $200,000.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Encompass Healthcare Billing, LLC [Member] | IDoc Virtual Telehealth Solutions, Inc [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Commitments, Contingencies, and Concentration Risk (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Business acquisition percentage of voting interests acquired |
|
|
|
|
|
|
|
|
|
100.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
| Encompass for a cash payment |
|
|
|
|
|
|
|
|
|
$ 300,000
|
|
|
|
|
|
|
|
|
|
|
|
|
| Interest expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 45,000
|
| Encompass purchase liability |
|
|
|
|
|
|
|
|
|
|
$ 400,000
|
|
$ 400,000
|
|
$ 650,000
|
|
$ 263,918
|
|
|
|
|
|
| Promissory Note and Line of Credit Relating to Forbearance Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Commitments, Contingencies, and Concentration Risk (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Basis spread on the variable rate |
|
|
|
|
|
3.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt instrument, variable interest rate, type [Extensible enumeration] |
|
|
|
|
|
prime rate
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Interest rate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6.75%
|
|
|
|
|
|
|
|
| Payments for forbearance |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 80,000
|
$ 20,000
|
|
| Periodic payment |
|
|
$ 100,000
|
$ 50,000
|
$ 25,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Periodic payment terms, balloon payment to be paid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1,541,106
|
|
|
|
|
|
|
| Equity Incentive Plan 2024 [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Commitments, Contingencies, and Concentration Risk (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Percentage of shares reserved for issuance |
|
|
|
|
|
|
|
|
|
|
|
|
15.00%
|
|
15.00%
|
|
|
|
|
|
|
|
| Number of shares issued (in Shares) | shares |
|
|
|
|
|
|
|
|
|
|
31,800
|
|
31,800
|
|
|
|
|
31,800
|
31,800
|
|
|
|
| Two Vendor [Member] | Supplier Concentration Risk [Member] | Accounts Payable and Accrued Liability [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Commitments, Contingencies, and Concentration Risk (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of suppliers |
|
|
|
|
|
|
|
|
|
|
|
|
2
|
|
2
|
|
|
|
|
|
|
|
| Investor [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Commitments, Contingencies, and Concentration Risk (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of deployed telepresence robots rights held (in robot) | robot |
|
|
|
|
|
|
|
|
|
|
|
|
8
|
|
8
|
|
|
|
|
|
|
|
| Percentage of monthly revenue generated from telepresence robots, considered for payment |
|
|
|
|
|
|
|
|
|
|
|
|
80.00%
|
|
80.00%
|
|
|
|
|
|
|
|
| Investor [Member] | IDoc Virtual Telehealth Solutions, Inc [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Commitments, Contingencies, and Concentration Risk (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Aggregate principal amount |
|
|
|
|
|
|
$ 200,000
|
$ 200,000
|
|
|
$ 200,000
|
|
$ 200,000
|
|
$ 200,000
|
|
|
|
|
|
|
|
| Number of deployed telepresence robots rights held (in robot) |
|
|
|
|
|
|
8
|
8
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Percentage of monthly revenue generated from telepresence robots, considered for payment |
|
|
|
|
|
|
80.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Telepresence robots deployed (in robot) |
|
|
|
|
|
|
8
|
8
|
|
|
|
|
8
|
|
8
|
|
|
|
|
|
|
|
| Minimum [Member] | Investor [Member] | IDoc Virtual Telehealth Solutions, Inc [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Commitments, Contingencies, and Concentration Risk (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Total number of deployed telepresence robots (in robot) | robot |
|
|
|
|
|
|
|
12
|
|
|
|
|
13
|
|
13
|
|
|
|
|
|
|
|
| Maximum [Member] | Investor [Member] | IDoc Virtual Telehealth Solutions, Inc [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Commitments, Contingencies, and Concentration Risk (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Total number of deployed telepresence robots (in robot) | robot |
|
|
|
|
|
|
|
20
|
|
|
|
|
20
|
|
20
|
|
|
|
|
|
|
|